Summary
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 27 molecules are developed by Companies. The latest report GMDHC22029TDB - Tyrosine Protein Kinase SYK - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 10, 2, 10 and 1 respectively.
Report covers products from therapy areas Oncology, Immunology, Ophthalmology, Dermatology, Hematological Disorders, Respiratory, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Diffuse Large B-Cell Lymphoma, Rheumatoid Arthritis, Allergic Conjunctivitis, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acquired (Autoimmune) Hemolytic Anemia, Asthma, Atopic Dermatitis (Atopic Eczema), Mantle Cell Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Epithelial Ovarian Cancer, Follicular Lymphoma, Kidney Transplant Rejection, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Respiratory Distress Syndrome, Allergies, Alopecia Areata, Alzheimer's Disease, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Fallopian Tube Cancer, Gastric Cancer, Hand Dermatitis, Hidradenitis Suppurativa, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Ocular Inflammation, Peritoneal Cancer, Psoriasis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified B-Cell Lymphomas, Unspecified Ophthalmological Disorders and Vitiligo.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AB Science SA
Alexion Pharmaceuticals Inc
Aptose Biosciences Inc
Archer Pharmaceuticals Inc
Asana BioSciences LLC
Beijing Hanmi Pharmaceutical Co Ltd
Calithera Biosciences Inc
Clevexel Pharma SA
CSPC Pharmaceutical Group Ltd
Genosco Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
IACTA Pharmaceuticals Inc
Japan Tobacco Inc
Kronos Bio Inc
Levolta Pharmaceuticals Inc
Nano Biotherapeutics Inc
Origenis GmbH
Pulmatrix Inc
Rigel Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
AB-8779 - Drug Profile
Product Description
Mechanism Of Action
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
cevidoplenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
History of Events
entospletinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
GNS-1653 - Drug Profile
Product Description
Mechanism Of Action
GS-492429 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GSK-2646264 - Drug Profile
Product Description
Mechanism Of Action
History of Events
gusacitinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-43239 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-265 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-270 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JTE-852 - Drug Profile
Product Description
Mechanism Of Action
lanraplenib succinate - Drug Profile
Product Description
Mechanism Of Action
History of Events
mivavotinib citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
nilvadipine - Drug Profile
Product Description
Mechanism Of Action
History of Events
piceatannol albumin bound - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PUR-1800 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit SYK and JAK for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit SYK for Ocular Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit H1-SYK for Unspecified Ophthalmic Diseases - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
sovleplenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYHX-1901 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAS-05567 - Drug Profile
Product Description
Mechanism Of Action
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Mar 08, 2022: Rigel announces publication of data from phase 2 clinical study of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia in the American Journal of Hematology
Jan 12, 2022: HUTCHMED receives Breakthrough Therapy designation in China for HMPL-523 for treatment of primary immune thrombocytopenia
Dec 21, 2021: Fostamatinib meets primary endpoint in phase 3 trial in Japan for treatment of chronic immune thrombocytopenia
Dec 14, 2021: HUTCHMED highlights HMPL-523 clinical data presented at the 2021 ASH Annual Meeting
Dec 13, 2021: HM43239 demonstrates durable clinical benefit in acute myeloid leukemia
Dec 06, 2021: Kronos Bio announces first patient dosed in AGILITY phase 3 clinical trial of entospletinib in patients with newly diagnosed NPM1-mutated acute myeloid leukemia
Nov 15, 2021: Rigel sharpens focus on its advanced portfolio opportunities
Nov 08, 2021: HUTCHMED highlights HMPL-523 clinical data to be presented at the 2021 ASH Annual Meeting
Oct 27, 2021: HUTCHMED initiates ESLIM-01, a phase III trial of HMPL-523 in patients with immune thrombocytopenia in China
Sep 01, 2021: Data from NIH/NHLBI-sponsored phase 2 trial of Fostamatinib in hospitalized COVID-19 patients published in clinical infectious diseases
Aug 13, 2021: Rigel Pharmaceuticals provides update on COVID-19 program
Jul 27, 2021: Kronos Bio announces FDA clearance of investigational new drug application for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)
Jul 14, 2021: New TAVALISSE data analyses to be presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
Jun 29, 2021: Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial
Apr 22, 2021: Asana BioSciences to present additional efficacy data from chronic hand eczema Phase 2b trial of oral SYK/JAK inhibitor Gusacitinib at AAD VMX late-breaking session
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AB Science SA, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Aptose Biosciences Inc, 2022
Pipeline by Archer Pharmaceuticals Inc, 2022
Pipeline by Asana BioSciences LLC, 2022
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2022
Pipeline by Calithera Biosciences Inc, 2022
Pipeline by Clevexel Pharma SA, 2022
Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Pipeline by Genosco Inc, 2022
Pipeline by GlaxoSmithKline Plc, 2022
Pipeline by Hutchison MediPharma Ltd, 2022
Pipeline by IACTA Pharmaceuticals Inc, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Kronos Bio Inc, 2022
Pipeline by Levolta Pharmaceuticals Inc, 2022
Pipeline by Nano Biotherapeutics Inc, 2022
Pipeline by Origenis GmbH, 2022
Pipeline by Pulmatrix Inc, 2022
Pipeline by Rigel Pharmaceuticals Inc, 2022
Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
